Neurology Residents Scholar Program
The NRSP is an epilepsy-focused educational opportunity for second- and third-year neurology residents. NRSP is an intensive multi-day course that addresses all clinical aspects of epilepsy, including the latest developments in diagnosis and treatment. Founded by the late Dr. John Gates of the Minnesota Epilepsy Group, PA, this is the NRSP’s eighteenth year educating residents about epilepsy to improve patient care. With epilepsy presenting in one-third of adult neurological disorders and more than two-thirds of pediatric neurological cases, the need to better inform general neurologists about this condition is essential.
The NRSP is presented by Creative Educational Concepts, Inc. (CEC) and is supported through independent educational grants from:
Platinum Level & Presenting Supporter: Greenwich Biosciences
Gold Level Supporter: UCB
Silver Level Supporters: Eisai and Neurelis
Bronze Level Supporter: SK Life Science, Inc.
Neurology residents/fellows who receive a nomination to attend the NRSP are selected by their program directors. Ideal candidates for the program are in their second or third year of residency, are committed to improving their diagnostic skills, and furthering their knowledge of the treatment of epilepsy. During this multi-day virtual meeting, residents attend interactive lectures and participate in breakout workshops in which they discuss clinical cases with colleagues from across the United States. Each resident is required to prepare and present one brief case study on an epilepsy-related topic of their choice. Participants who attend the 2020 NRSP will receive a detailed electronic handout and several other resources relating to the diagnosis and treatment of epilepsy. Thank you for your interest in the 2020 Neurology Residents Scholar Program. If you have any questions about this program, please contact Ashley C. Lilly, Account Director, at (866) 360-1717 or email@example.com.
Neurology PGY-2/PGY-3 residents in accredited U.S. training programs who are providing care in epilepsy.
At the conclusion of this activity, participants will be able to:
- Classify seizure types according to the newly proposed International League Against Epilepsy (ILAE) guidelines and recognize clinical presentation of common seizure types.
- Assess etiology of seizures by age of onset and risk factors and anticipate risk of recurrence.
- Review the neurobiology of epilepsy, including mechanisms of epileptogenesis and role of kindling in the development of epilepsy.
- Explore genetic testing involved in the diagnostic work-up for infants with recurrent seizures and how best to differentiate Dravet syndrome from other infantile-onset epileptic encephalopathies, including infantile spasms and Lennox-Gastaut syndrome (LGS).
- Explore novel treatments for Dravet syndrome and LGS, comparing efficacy data, adverse events, pharmacokinetic parameters, and other practical issues involved in their use in infants and children.
- Outline evidence-based antiepileptic treatment options with regard to mechanism of action, efficacy, pharmacokinetic profile, drug interactions, and risk of adverse effects.
- Identify benign versus malignant epilepsy syndromes that occur in children, their EEG characteristics, and clinical prognosis.
- Identify basic benign and abnormal waveforms involved in interpretation of EEGs with a review of frequency, amplitude, and location.
- Evaluate the child with seizures and epilepsy with regard to etiology, prognosis, treatment, and psychosocial issues.
- Identify when refractory patients are candidates for surgery, neurostimulation, or other invasive treatments and desired outcomes of these interventions.
- Consider impact of CT, MRI, fMRI, MRS, MSI, SPECT, and PET findings on epilepsy and other relevant neurological abnormalities as they relate to diagnosis, treatment, and presurgical planning.
- Develop appropriate treatment plans for the female patient with epilepsy that consider impact of hormones, pregnancy, and risk for long-term adverse events such as osteoporosis.
- Provide appropriate guidance to a patient and family in the early part of their disease course with regard to prognosis, safety concerns/driving, and treatment decision-making.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Heidi Currier, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Edward Hogan, MD–has disclosed that he is a consultant for Neurelis Inc.; he receives grant/research support from Neurelis Inc., Biogen, Inc., Eisai, Engage Therapeutics.
Andres M. Kanner, MD, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.
Theodore J. Passe, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Patricia Penovich, MD–has disclosed that she is a consultant for UCB; and is a member of the speakers' bureaus for Lundbeck, Sunovion, and UCB.
Douglas M. Smith, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Michael C. Smith, MD–has disclosed that he receives grant/research support from Neuropace.
David Spencer, MD, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.
Elizabeth A. Thiele, MD, PhD–had disclosed that she is a consultant for Greenwich Biosciences, UCB, and Zogenix and receives grant/research support from GW Pharmaceuticals.
Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for up to 11 AMA PRA Category 1 Credits™. Participants will be provided instructions for receiving credit through Creative Educational Concepts’ web portal, CE Spectrum, at the live activity.
- 11.00 AMA PRA Category 1 Credit™